Bacterial overgrowth as a cause of irritable bowel syndrome

Current Opinion in Gastroenterology

Volumn 22, Issue 6, 2006, Pages 669-673

  Riordan, Stephen M ^a,b   Kim, Robert ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Bacterial overgrowth; Gut flora; Irritable bowel syndrome

Indexed keywords

BACITRACIN; HYDROGEN; METRONIDAZOLE; NEOMYCIN; PROBIOTIC AGENT; RIFAXIMIN;

ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM BIFIDUM; BLOATING; BREATH ANALYSIS; ESCHERICHIA COLI; FECES MICROFLORA; HUMAN; IMMUNOREACTIVITY; INTESTINE MUCOSA; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS REUTERI; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PREVALENCE; RAT STRAIN; REVIEW; SMALL INTESTINE; SYMPTOM;

ANIMALS; BACTERIA; HUMANS; INTESTINAL MUCOSA; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME; PROBIOTICS; RISK FACTORS;

EID: 33750360362     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000245544.80160.46     Document Type: Review

References (27)

1. Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006; 101:334-335. A comprehensive review of recent findings suggesting an effect of gut flora on symptoms of IBS.
2. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124:1662-1671.
3. Alun-Jones V, Wilson AJ, Hunter JO, et al. The aetiological role of antibiotic prophylaxis with hysterectomy in irritable bowel syndrome. J Obstet Gynaecol 1984; 5:S22-S23.
4. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347:150-153.
5. Verdu EF, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55:182-190. An important study indicating interactions between gut flora, mucosal inflammation and visceral hypersensitivity in a murine model. The findings suggest a beneficial therapeutic effect of a specific probiotic strain.
6. Verdu EF, Bercik P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127:826-837.
7. Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100:2560-2568. This review focuses on data in support of interactions between gut flora and intestinal motility.
8. Husebye E, Hellstrom PM, Sundler F, et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280:G368-G380.
9. Si J-M, Yu Y-C, Fan Y-J, Chen S-J. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10:1802-1805.
10. Passos MC, Serra J, Azpiroz F, et al. Impaired reflex control of intestinal gas transit in patients with abdominal bloating. Gut 2005; 54:344-348. This study suggests a mechanism for reduced intestinal motility in patients with IBS.
11. Azpiroz F. Intestinal gas dynamics: mechanisms and clinical relevance. Gut 2005; 54:893-895.
12. Bercik P, Wang L, Verdu EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of post infective gut dysfunction. Gastroenterology 2004; 127:179-187.
13. Moshiree B, Zhou Q, Price DD, Verne GN. Central sensitization in visceral pain disorders. Gut 2006; 55:905-908.
14. Kamiya T, Wang L, Forsythe P, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55:191-196. An important study that provides insight to the mechanism of visceral pain induced by colorectal distension and a beneficial effect of a specific probiotic strain on neural function.
15. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-419.
16. Parisi G, Leandro G, Bottona E, et al. Small intestinal bacterial overgrowth and irritable bowel syndrome. Am J Gastroenterol 2003; 98:2572.
17. 14C D-xylose and healthy controls. Am J Gastroenterol 2005; 100:1566-1570. A study that suggests that the prevalence of small intestinal bacterial overgrowth in patients with IBS is not increased compared to healthy controls.
18. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22:1157-1160. A study that suggests that the prevalence of small intestinal bacterial overgrowth in patients with IBS is significantly higher than in healthy controls.
19. Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996; 91:1795-1803.
20. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome. Dig Dis Sci 2005; 50:758-766.
21. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101:324-331.
22. Kurtovic J, Segal I, Riordan SM. Culture-proven small intestinal bacterial overgrowth as a cause of irritable bowel syndrome: response to lactulose but not broadspectrum antibiotics. J Gastroenterol 2005; 40:767-770.
23. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-551.
24. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17:687-696.
25. Kajander K, Hatakka K, Poussa T, et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22:387-394.
26. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24:925-931.
27. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005; 147:197-201. Together with [23-26], reports results of clinical trials of probiotic therapy in patients with IBS, extending previously reported observations.